Nanoparticle-delivered miR-486-5p inhibits H(2)O(2)-induced injury in cultured endothelial and kidney tubular epithelial cells.

阅读:4
作者:Maadelat Ali O, Wehella Savindi, Douvris Adrianna, Manturthi Shireesha, Burns Kevin D, Gadde Suresh
Acute kidney injury (AKI) is a serious condition characterized by a sudden decrease in kidney function, often leading to chronic kidney disease. Current treatment options are limited, necessitating novel therapeutic strategies. We previously showed that microRNA-486-5p (miR-486-5p) protects against AKI by regulating cell death (apoptosis) both in vitro and in vivo. However, efficient and selective delivery remains a challenge. In this study, we designed and developed nanoparticles (NPs) to encapsulate and deliver miR-486-5p to cultured endothelial and kidney tubular epithelial cells. NPs were characterized and optimized for size, polydispersity index, surface charge, and encapsulation efficiency. The stability of NPs in long-term storage and in biological solutions was confirmed. Results indicated effective cellular uptake of NPs, cargo microRNA delivery to the intracellular environment, and the absence of cytotoxicity upon NP treatment. Functional assessments showed that miR-486-5p-encapsulating lipid-polymeric hybrid NPs (HNPs) suppressed the expression of Forkhead Box Protein O1 (FOXO1), a validated target of miR-486-5p, in all cell lines investigated, suggesting effective miR-486-5p protection and transport. Both endothelial and tubular epithelial cells were significantly protected against induced apoptosis when pretreated with miR-486-5p-encapsulating HNPs. However, selective siRNA-mediated knockdown of FOXO1 did not result in injury protection, suggesting involvement of other miR-486-5p targets. Furthermore, cell injury-induced expression of inflammatory cytokines was inhibited by HNP-delivered miR-486-5p in both cell lines. These findings demonstrate the protective and anti-inflammatory effects of miR-486-5p-HNP systems in injured endothelial and tubular epithelial cells, highlighting their capacity as a potential nano-therapy for AKI and paving the way for in vivo studies and clinical applications.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。